The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
The move marks a step in the effort to improve antibody quality as the life science community becomes increasingly aware of the problem of faulty reagents.
The partners will continue to develop an integrated sequence and knowledge database to support Pierre Fabre's therapeutic antibody development efforts.
Caprion, Asuragen, and the AIT Austrian Institute of Technology join the consortium launched in 2013 to develop blood-based tests for the early detection of cancers.
